Eris Lifesciences Q1 FY27 results: revenue up 13%, PAT up 15% YoY

EBITDA margin compressionResults View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.5%Reaction day

₹1390.00

prior close

₹1391.70

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.3%+1.2% vs market

Pharmaceuticals peers, median of 160sector+0.8%+1.8% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty Smallcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+0.9

15m

+1.2

30m

+2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.5+1.3+1.2+0.8+1.8

Next day

-0.7+0.6-1.3+0.0-0.7

-2.2+1.0-3.2+0.1-2.2

-0.1+2.4-2.5+0.6-0.8

-0.9+2.6-3.4+1.0-1.9

-1.1+3.3-4.4+0.6-1.7

-0.3+3.5-3.8+1.6-1.9

15d

-2.9+2.8-5.6+0.5-3.4

-6.1+3.6-9.7+2.1-8.2

-12.2+0.0-12.2+4.2-16.4

-16.1-3.6-12.5-1.9-14.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences reported Q1 FY27 (quarter ended June 30, 2026) consolidated revenue from operations of Rs 873.25 crores, up about 13% from Rs 773 crores in Q1 FY26. Net profit rose around 15% to Rs 143.32 crores. Basic EPS stood at Rs 10.28 versus Rs 8.66 YoY. Operating margin dipped to 25.94% from 27.02% in Q1 FY26. Auditor Walker Chandiok issued an unmodified review report. Board also reappointed Kiran J Mehta and Co as cost auditors for FY27.

Likely market impact

Steady quarter with double-digit revenue and profit growth. Slight operating margin dip is watchable. Unmodified auditor opinion is reassuring.